This trial is testing how well ramucirumab and paclitaxel or the FOLFIRI regimen work in treating patients with small bowel cancers that have spread extensively or are no longer responding to treatment.
1 Primary · 3 Secondary · Reporting Duration: Up to 3 years after registration
94 Total Participants · 2 Treatment Groups
Primary Treatment: Ramucirumab · No Placebo Group · Phase 2
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: